A leading developer in the treatment of multiple sclerosis (MS), BioMS Medical Corp (TSE: MS) \, recently announced that the University of Alberta has received additional patents for the Company's synthetic peptide therapeutic, MBP8298, for the treatment of multiple sclerosis (MS).
These patents are licensed by BioMS Medical on an exclusive worldwide basis from the University of Alberta.
The most recent patent, entitled "Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient" has been granted in the United States and addresses methods of predicting efficacy of certain courses of treatment for MS patients.
BioMS has exclusive licenses to 99 granted patents in 34 countries worldwide.
Read the full press release.
Comment Preview